Clinical and aconomic evaluation of phosphocreatine (Neoton) administration during cardiac surgery with extracorporeal ciculation.
Material and methods
Modelling was used to evaluate cost-effectiveness and budget impact of phosphocreatine and levosimendan administration during cardiac surgey. Efficacy of two medication was compared by network meta-analysis.
Perioperative phosphocreatine administration during extracorporeal circulation results in a lower risk of unfavorable outcomes including myocardial infarction, serious arrhythmias and inotropic requirement compared to the standard treatment, and is 42.8% cheaper compared to levosimendan administration.
Phosphocreatine administration during cardiac surgery is cost saving and more effective that levosimendan administration.
Pharmacoeconomics, budget impact analysis, cardiac protection, cardiac surgery, phosphocreatine.